Abbott Laboratories Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Abbott Laboratories heeft een totaal eigen vermogen van $40.0B en een totale schuld van $15.0B, wat de schuld-eigenvermogensverhouding op 37.6% brengt. De totale activa en totale passiva bedragen respectievelijk $74.4B en $34.3B. De EBIT Abbott Laboratories is $7.6B waardoor de rentedekking 31.7 is. Het heeft contanten en kortetermijnbeleggingen van $7.8B.
Belangrijke informatie
37.6%
Verhouding schuld/eigen vermogen
US$15.05b
Schuld
| Rente dekkingsratio | 31.7x |
| Contant | US$7.79b |
| Aandelen | US$40.03b |
| Totaal verplichtingen | US$34.33b |
| Totaal activa | US$74.36b |
Recente financiële gezondheidsupdates
Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?
Oct 11
These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well
Jul 01Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Recent updates
Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist
Oct 31Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Oct 21Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Oct 14Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?
Oct 11Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price
Sep 27Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Sep 11A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Aug 16Abbott Laboratories: Driving Value By Scaling Innovations
Aug 13Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors
Aug 05Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough
Jul 13These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well
Jul 01Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price
Jun 18Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)
Jun 04Abbott Laboratories: Why I Agree With Wall Street On This One
Jun 04Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock
May 18Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now
Mar 21Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger
Mar 19Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
Feb 27Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon
Feb 08The King Is Back: Abbott Laboratories' Path To >11% Annual Returns
Jan 29The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts
Jan 26Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $23.8B ) ABT } overtreffen de korte termijn passiva ( $14.9B ).
Langlopende schulden: De kortetermijnactiva ABT ( $23.8B ) overtreffen de langetermijnschulden ( $19.4B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 18.1% ) ABT wordt als voldoende beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van ABT is de afgelopen 5 jaar gedaald van 59.6% naar 37.6%.
Schuldendekking: De schuld van ABT wordt goed gedekt door de operationele kasstroom ( 58% ).
Rentedekking: De rentebetalingen op de schuld van ABT worden goed gedekt door EBIT ( 31.7 x dekking).